193 related articles for article (PubMed ID: 23136004)
1. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.
Zoja C; Corna D; Nava V; Locatelli M; Abbate M; Gaspari F; Carrara F; Sangalli F; Remuzzi G; Benigni A
Am J Physiol Renal Physiol; 2013 Mar; 304(6):F808-19. PubMed ID: 23136004
[TBL] [Abstract][Full Text] [Related]
2. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity.
Chin M; Lee CY; Chuang JC; Bumeister R; Wigley WC; Sonis ST; Ward KW; Meyer C
Am J Physiol Renal Physiol; 2013 Jun; 304(12):F1438-46. PubMed ID: 23594825
[TBL] [Abstract][Full Text] [Related]
3. The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome: When Marketing Interests Prevail over Patients Clinical Needs.
Ruggenenti P
Nephron; 2023; 147(8):465-469. PubMed ID: 36731435
[TBL] [Abstract][Full Text] [Related]
4. The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells.
Ding Y; Stidham RD; Bumeister R; Trevino I; Winters A; Sprouse M; Ding M; Ferguson DA; Meyer CJ; Wigley WC; Ma R
Kidney Int; 2013 May; 83(5):845-54. PubMed ID: 23235569
[TBL] [Abstract][Full Text] [Related]
5. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Shelkovnikov S; Farzaneh SH; Khazaeli M; Meyer CJ
Redox Biol; 2013; 1(1):527-31. PubMed ID: 24363993
[TBL] [Abstract][Full Text] [Related]
6. Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats.
Schäfer S; Linz W; Bube A; Gerl M; Huber J; Kürzel GU; Bleich M; Schmidts HL; Busch AE; Rütten H
Cardiovasc Res; 2003 Nov; 60(2):447-54. PubMed ID: 14613875
[TBL] [Abstract][Full Text] [Related]
7. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Rossing P; Block GA; Chin MP; Goldsberry A; Heerspink HJL; McCullough PA; Meyer CJ; Packham D; Pergola PE; Spinowitz B; Sprague SM; Warnock DG; Chertow GM
Kidney Int; 2019 Oct; 96(4):1030-1036. PubMed ID: 31377056
[TBL] [Abstract][Full Text] [Related]
8. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease.
Tan SM; Sharma A; Stefanovic N; Yuen DY; Karagiannis TC; Meyer C; Ward KW; Cooper ME; de Haan JB
Diabetes; 2014 Sep; 63(9):3091-103. PubMed ID: 24740568
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease.
Vaziri ND; Liu S; Farzaneh SH; Nazertehrani S; Khazaeli M; Zhao YY
Free Radic Biol Med; 2015 Sep; 86():374-81. PubMed ID: 25930007
[TBL] [Abstract][Full Text] [Related]
10. Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function.
Nagasu H; Sogawa Y; Kidokoro K; Itano S; Yamamoto T; Satoh M; Sasaki T; Suzuki T; Yamamoto M; Wigley WC; Proksch JW; Meyer CJ; Kashihara N
FASEB J; 2019 Nov; 33(11):12253-12263. PubMed ID: 31431054
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
Kojima N; Williams JM; Takahashi T; Miyata N; Roman RJ
J Pharmacol Exp Ther; 2013 Jun; 345(3):464-72. PubMed ID: 23492941
[TBL] [Abstract][Full Text] [Related]
12. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.
Aminzadeh MA; Reisman SA; Vaziri ND; Khazaeli M; Yuan J; Meyer CJ
Xenobiotica; 2014 Jun; 44(6):570-8. PubMed ID: 24195589
[TBL] [Abstract][Full Text] [Related]
13. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
14. Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.
Thallas-Bonke V; Coughlan MT; Bach LA; Cooper ME; Forbes JM
Am J Nephrol; 2010; 32(1):73-82. PubMed ID: 20551625
[TBL] [Abstract][Full Text] [Related]
15. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
de Zeeuw D; Akizawa T; Audhya P; Bakris GL; Chin M; Christ-Schmidt H; Goldsberry A; Houser M; Krauth M; Lambers Heerspink HJ; McMurray JJ; Meyer CJ; Parving HH; Remuzzi G; Toto RD; Vaziri ND; Wanner C; Wittes J; Wrolstad D; Chertow GM;
N Engl J Med; 2013 Dec; 369(26):2492-503. PubMed ID: 24206459
[TBL] [Abstract][Full Text] [Related]
16. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Chertow GM; Appel GB; Block GA; Chin MP; Coyne DW; Goldsberry A; Kalantar-Zadeh K; Meyer CJ; Molitch ME; Pergola PE; Raskin P; Silva AL; Spinowitz B; Sprague SM; Rossing P
J Diabetes Complications; 2018 Dec; 32(12):1113-1117. PubMed ID: 30318163
[TBL] [Abstract][Full Text] [Related]
17. Bardoxolone methyl: drug development for diabetic kidney disease.
Kanda H; Yamawaki K
Clin Exp Nephrol; 2020 Oct; 24(10):857-864. PubMed ID: 32594372
[TBL] [Abstract][Full Text] [Related]
18. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).
Impellizzeri D; Esposito E; Attley J; Cuzzocrea S
Pharmacol Res; 2014 Mar; 81():91-102. PubMed ID: 24602801
[TBL] [Abstract][Full Text] [Related]
19. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
[TBL] [Abstract][Full Text] [Related]
20. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
de Zeeuw D; Akizawa T; Agarwal R; Audhya P; Bakris GL; Chin M; Krauth M; Lambers Heerspink HJ; Meyer CJ; McMurray JJ; Parving HH; Pergola PE; Remuzzi G; Toto RD; Vaziri ND; Wanner C; Warnock DG; Wittes J; Chertow GM
Am J Nephrol; 2013; 37(3):212-22. PubMed ID: 23467003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
